FindTrial
Sign In

Effects of Metformin on Coronary Microvascular Function and Expression of E3 / UBPL Parkin Protein of Serum in Patients with Type 2 diabetics

Effects of Metformin on Coronary Microvascular Function and Expression of E3 / UBPL Parkin Protein of Serum in Patients with Type 2 diabetics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-16009800
Enrollment
Unknown
Registered
2016-11-09
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

1:metformin treatment
2:non-metformin treatment

Sponsors

The First Clinical Medical School, Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of type 2 diabetes complys with the world health organization (WHO) clinical diagnostic criteria for T2DM in 1999; 2. the ratio of coronary stenosis is less than 50% confirmed by coronary angiography.

Exclusion criteria

Exclusion criteria: 1. The ratio of coronary stenosis is not less than 50% confirmed by coronary angiography; 2. Treated with metformin irregularly or less than 3 months.

Design outcomes

Primary

MeasureTime frame
coronary flow reserve;myocardial blood flow;—

Secondary

MeasureTime frame
E3/UBPL Parkin;—

Countries

China

Contacts

Public ContactWu Weihua

The First Affiliated Hospital of Harbin Medical University

hui-90@163.com+86 13945062678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026